GHRH receptor agonist identical in mechanism to Mod-GRF(1-29). Lacks cysteine-maleimide conjugation that enables DAC albumin binding. Half-life governed by DPP-IV resistance from substituted amino acids alone (~15–30 min). Produces clean, pulsatile GH release closely mimicking endogenous patterns.
Studies have administered: 100–200mcg per injection, typically combined with GHRP; 2–3x daily dosing
Robust pulsatile GH release verified. Synergy with ipamorelin and GHRP class well-documented. Preferred over DAC variant for sleep-time GH pulse research (mimics physiological nocturnal GH surge).
Flushing (transient); injection site reactions; water retention with continued use; minimal cortisol/prolactin elevation (unlike GHRPs)
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on CJC-1295 (No DAC) — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat